OUR APPROACH

​

EVOQ Therapeutics is pioneering the development of a proprietary technology that represents a genuine breakthrough for autoimmune disease and cancer therapy.

​

Autoimmune Disease Vaccines

​

EVOQ's technology has demonstrated breakthrough efficacy in the gold-standard EAE model for Multiple Sclerosis (MS). Success with this preclinical model is considered proof of concept for the potential utility of a therapy in a wide range of autoimmune diseases.

​

With prevalence on the rise, Autoimmune diseases have a devastating impact on the lives of millions of children and adults around the world.

​

Examples include:

  • Type 1 Diabetes

  • Celiac disease

  • Multiple sclerosis

  • Neuromyelitis optica

  • Rheumatoid arthritis

  • Myasthenia gravis

  • Pemphigus

  • Graves' disease

​

EVOQ is now engaged in preclinical studies for a number of autoimmune diseases.
 

Cancer Vaccines

​

EVOQ has demonstrated that delivering antigens and adjuvants with our vaccine platform evokes an immune response that is 30 times more powerful than the best antigen adjuvant combinations.

​

Our vaccine produces robust anti-tumor immunity against new tumor epitopes (regardless of pre-existing immunity) while broadening T-cell responses against multiple tumor epitopes.

​

Furthermore, when used in combination with immune checkpoint inhibitors, our vaccine generates striking levels of anti-tumor immunity that eradicates established tumors and protects animals against tumor recurrence.

​

Preclinical efficacy has been demonstrated in multiple cancer types including: 

  • Colon Cancer

  • Melanoma

  • HPV-associated Lung

  • HPV-associated Head & Neck

  • KRAS-associated cancers

  • Glioblastoma multiforme

EVOQ's technology utilizes a proprietary synthetic HDL NanoDisc that has been optimized to deliver antigens (with or without adjuvants) to Dendritic cell depots located in lymph nodes.

​

EVOQ'S NanoDisc Vaccines have...

​

  • Produced superior T-cell responses through more effective targeting of the lymph-system. 

​​

  • The versatility required for efficient delivery of wide range of peptides and adjuvants in a simple SC injection. It has been tested with Poly IC:LC, CpG, and a diverse set of more than 140 peptides to date.

​

  • An exceptionally clean safety profile - already tested in man

​

  • A well characterized manufacturing schema with 2+ years of stability